By proceeding, you agree to our Terms of Use and Privacy Policy.
Dr. Cao is the Co-founder and CEO at BridGene Biosciences, Inc. He has 18+ years of biopharma industry experience in both large and small molecule drug discovery research. He is an expert in biophysical/biochemical characterization of proteins/peptides, focusing on leveraging mass spectrometry to support the biopharmaceutical pipeline. His teams have helped advance multiple programs into the clinic in a variety of disease indications, including diabetes, obesity, dyslipidemia,and cardiovascular disease.Dr. Cao has held various managerial positions throughout his career. He was responsible for establishing a state-of-the-art mass spectrometry and analytical group at Tularik, Inc., which was acquired by Amgen in 2004. Most recently, Dr. Cao was a Principal Scientist in the Discovery Analytical Attributes Group at Amgen, Inc. His group engaged in hypothesis-driven targeted proteomics to complement Amgen’s genetic discovery platform, with the goal of facilitating seamless and rapid advancement of projects from research to commercialization.
Talks About #DrugDiscovery #Biotechnology #Chromatography
Preferred Locations #NorthAmerica